166 related articles for article (PubMed ID: 7395889)
1. Hemodialysis of mefenamic acid in uremic patients.
Wang LH; Lee CS; Marbury TC
Am J Hosp Pharm; 1980 Jul; 37(7):956-8. PubMed ID: 7395889
[TBL] [Abstract][Full Text] [Related]
2. Hemodialysis clearance of ethosuximide in patients with chronic renal disease.
Marbury TC; Lee CS; Perchalski RJ; Wilder BJ
Am J Hosp Pharm; 1981 Nov; 38(11):1757-60. PubMed ID: 7304633
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetics of dyphylline elimination by uremic patients.
Lee CC; Wang LH; Majeske BL; Marbury TC
J Pharmacol Exp Ther; 1981 May; 217(2):340-4. PubMed ID: 7229976
[TBL] [Abstract][Full Text] [Related]
4. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.
Brandi L
Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159
[TBL] [Abstract][Full Text] [Related]
5. Differential effect of chronic renal failure on the pharmacokinetics of lidocaine in patients receiving and not receiving hemodialysis.
De Martin S; Orlando R; Bertoli M; Pegoraro P; Palatini P
Clin Pharmacol Ther; 2006 Dec; 80(6):597-606. PubMed ID: 17178261
[TBL] [Abstract][Full Text] [Related]
6. Hemodialysis clearance and total body elimination of carbamazepine during chronic hemodialysis.
Lee CS; Wang LH; Marbury TC; Bruni J; Perchalski RJ
Clin Toxicol; 1980 Oct; 17(3):429-38. PubMed ID: 7449356
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetics of L-carnitine in patients with end-stage renal disease undergoing long-term hemodialysis.
Evans AM; Faull R; Fornasini G; Lemanowicz EF; Longo A; Pace S; Nation RL
Clin Pharmacol Ther; 2000 Sep; 68(3):238-49. PubMed ID: 11014405
[TBL] [Abstract][Full Text] [Related]
8. Changes in plasma concentrations of hypoxanthine and uric acid before and after hemodialysis.
Shahbazian H; Zand Moghadam A; Ehsanpour A; Khazaali M
Iran J Kidney Dis; 2009 Jul; 3(3):151-5. PubMed ID: 19617664
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetic aspects of digoxin in patients with terminal renal failure. II. On hemodialysis.
van der Vijgh WJ
Int J Clin Pharmacol Biopharm; 1977 Jun; 15(6):255-9. PubMed ID: 881277
[TBL] [Abstract][Full Text] [Related]
10. Effect of hemodialysis on total body clearance of chloramphenicol.
Slaughter RL; Cerra FB; Koup JR
Am J Hosp Pharm; 1980 Aug; 37(8):1083-6. PubMed ID: 7405936
[TBL] [Abstract][Full Text] [Related]
11. Absorption and disposition of ibuprofen in hemodialyzed uremic patients.
Senekjian HO; Lee CS; Kuo TH; Au DS; Krothapalli R
Eur J Rheumatol Inflamm; 1983; 6(2):155-62. PubMed ID: 6673979
[TBL] [Abstract][Full Text] [Related]
12. Disposition of didanosine in HIV-seropositive patients with normal renal function or chronic renal failure: influence of hemodialysis and continuous ambulatory peritoneal dialysis.
Knupp CA; Hak LJ; Coakley DF; Falk RJ; Wagner BE; Raasch RH; van der Horst CM; Kaul S; Barbhaiya RH; Dukes GE
Clin Pharmacol Ther; 1996 Nov; 60(5):535-42. PubMed ID: 8941026
[TBL] [Abstract][Full Text] [Related]
13. [Pharmacokinetics of ceftriaxone in hemodialysis].
Laville M; Mercatello A; Freney J; Pozet N; Meugnier H; Labeeuw M; Fleurette J; Zech P
Pathol Biol (Paris); 1987 Jun; 35(5 Pt 2):719-23. PubMed ID: 3309803
[TBL] [Abstract][Full Text] [Related]
14. Single-dose pharmacokinetics of teicoplanin during hemodialysis therapy using high-flux polysulfone membranes.
Thalhammer F; Rosenkranz AR; Burgmann H; Graninger W; Hollenstein U; Schenk P; Thalhammer-Scherrer R; Traindl O; Hörl WH; Breyer S
Wien Klin Wochenschr; 1997 May; 109(10):362-5. PubMed ID: 9200809
[TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetics of vancomycin when administered during high flux hemodialysis.
Foote EF; Dreitlein WB; Steward CA; Kapoian T; Walker JA; Sherman RA
Clin Nephrol; 1998 Jul; 50(1):51-5. PubMed ID: 9710347
[TBL] [Abstract][Full Text] [Related]
16. [The treatment of hyperhomocysteinemia in patients on dialysis: folic acid or the high-flow polysulphonic membrane?].
Lovcić V; Kes P; Zeljko R; Kusec V
Acta Med Croatica; 2006 Jun; 60(3):201-8. PubMed ID: 16933832
[TBL] [Abstract][Full Text] [Related]
17. Comparison of temsirolimus pharmacokinetics in patients with renal cell carcinoma not receiving dialysis and those receiving hemodialysis: a case series.
Lunardi G; Armirotti A; Nicodemo M; Cavallini L; Damonte G; Vannozzi MO; Venturini M
Clin Ther; 2009 Aug; 31(8):1812-9. PubMed ID: 19808140
[TBL] [Abstract][Full Text] [Related]
18. Hemodialysis clearance of total and unbound lidocaine.
Jacobi J; McGory RW; McCoy H; Matzke GR
Clin Pharm; 1983; 2(1):54-7. PubMed ID: 6883930
[TBL] [Abstract][Full Text] [Related]
19. Accumulation of vitamin E metabolites in the blood of renal failure patients.
Galli F; Floridi AG; Floridi A; Buoncristiani U
Clin Nutr; 2004 Apr; 23(2):205-12. PubMed ID: 15030960
[TBL] [Abstract][Full Text] [Related]
20. Citrate kinetics in patients receiving long-term hemodialysis therapy.
Bauer E; Derfler K; Joukhadar C; Druml W
Am J Kidney Dis; 2005 Nov; 46(5):903-7. PubMed ID: 16253731
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
